Table 7.

Tumor response

TreatmentCR (%)PR (%)SD (%)
Erlotinib (n = 424)4 (1)34 (8)150 (35)
Placebo (n = 210)1 (.5)1 (.5)56 (27)
  • NOTE: Patients with measurable disease at study entry who received at least one dose of erlotinib or placebo. CR + PR, P< 0.0001 (Fisher's exact test). CR + PR + SD, P < 0.0001 (Fisher's exact test).

  • Abbreviations: CR, complete response; PR, partial response; SD, stable disease.